Latest news with #ClinicalDevelopment
Yahoo
04-08-2025
- Business
- Yahoo
AB Science announces the successful completion of a 2.55 million euros private placement
PRESS RELEASE AB SCIENCE ANNOUNCES THE SUCCESSFUL COMPLETION OF A EUR 2.55 MILLION PRIVATE PLACEMENT Paris, August 4, 2025, 8am CET AB Science S.A. (the 'Company' or 'AB Science', Euronext – FR0010557264 – AB) announces today the successful completion of a capital increase of a total gross amount of EUR 2.55 million subscribed by a limited number of investors (the 'Private Placement'). The Private Placement is not subject to a prospectus requiring an approval from the French Financial Market Authority (Autorité des Marchés Financiers – the 'AMF'). In accordance with Article 1.5.(ba) of the Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017, as amended (the 'Prospectus Regulation'), the Company file with the AMF a document containing the information set out in Appendix IX of the Prospectus Regulation (the 'Information document'), copies of which will be available free of charge on the Company's website at and on the AMF's website at Use of proceeds The Company intends to use the net proceeds of the Private Placement to finance its ongoing activities, with a focus on the clinical development of the AB8939 program. This transaction strengthens the Company's cash position and enables it to cover its financing needs in 2025 and beyond the next 12 months, taking into account the explanations set out in section 5.2.1.5 (note 2) of the 2024 financial report. Terms and conditions of the Private Placement The Private Placement, for a total amount of EUR 2.55 million (including share issue premium), was carried out through the issuance, without preferential subscription rights and without a priority subscription period, of 2,276,787 new ordinary shares of the Company (the 'New Shares'), each with one share warrant attached (a 'BSA' and, together with the New Share to which it is attached, an 'ABSA'), as part of a share capital increase with cancellation of shareholders' preferential subscription rights for the benefit of investors within the category of persons defined by the 16th resolution of the Combined General Meeting of the Company's shareholders of June 30, 2025 (the 'General Meeting'), in accordance with Article L. 225-138 of the French commercial code (the 'Private Placement'). The issue of the ABSAs, representing approximately 3.34% of the Company's share capital, on a non-diluted basis, before completion of the Private Placement, and 3.23% of the Company's share capital, on a non-diluted basis, after completion of the Private Placement, was decided on August 1st, 2025 by the Chief Executive Officer, pursuant to the delegation of competence granted to him by the board of directors dated July 24, 2025, pursuant to the delegation of competence granted to it under the 16th resolution of the General Meeting . The issue price of one ABSA is EUR 1.12 (including share issue premium), representing a facial discount of 24.68% (i.e. EUR 0.3669) to the volume-weighted average price of the AB Science shares on the regulated market of Euronext Paris ('Euronext Paris') over the three trading days preceding the setting of such issue price, i.e. August 1st and July 31 and 30, 2025 (the '3-day VWAP'). The issue price of an ABSA, including the theoretical value of the BSA attached to it (as described below, together with the exercise price of such BSA) represents a total 17.87% discount per AB Science share to the 3-day VWAP, consistent with the maximum discount authorized by the General Meeting pursuant to its 16th resolution. Terms and conditions of the BSA One BSA is attached to each New Share. One BSA entitles their holder to subscribe to one new ordinary share of the Company, at a price of EUR 1.71 per ordinary share. The BSAs may be exercised at any time within 60 months of their issuance. In the event all BSAs are exercised, a total number of 2,276,787 additional ordinary shares of the Company will be issued, representing additional total proceeds of approximately EUR 3.89 million. The theoretical value of each BSA, assuming a volatility of 34.355%1 and based on closing price as of August 1st, 2025, is equal to EUR 0.3877 using Black & Scholes model. The BSAs will be immediately detached (détachés) from the New Shares upon issuance and are expected to be listed on Euronext Growth Paris ('Euronext Growth Paris') on or prior to August 11, 2025. Impact of the Private Placement on the Company's shareholding Following the issuance of the ABSAs, the Company's total share capital will be EUR 704,695.95 (or EUR 727,463.82 in the event of exercise of all BSAs). It will be comprised of 63,706,916 ordinary shares (or of 65,983,703 ordinary shares in the event of exercise of all BSAs) with a par value of EUR 0.01. There will be no change on the number of preferred shares. To the Company's knowledge, immediately prior to completion of the Private Placement and after completion of the Private Placement, the breakdown of the Company's share capital is as follows: Shareholders Before the capital increase After the capital increase (before exercising the warrants) After the capital increase and exercise of the warrant Number of shares ( 1) % Diluted base ( 2) Number of shares ( 1) % Diluted base ( 2) Number of shares ( 1) % Diluted base ( 2) A. Moussy 7 345 396 10,77% 17,57% 7 345 396 10,42% 17,12% 7 345 396 10,10% 16,69% AMY SAS (3) 12 273 000 18,00% 14,20% 12 273 000 17,42% 13,84% 12 273 000 16,87% 13,49% Subtotal concert A. Moussy 19 618 396 28,77% 31,77% 19 618 396 27,84% 30,96% 19 618 396 26,97% 30,18% Other investors members of the concert 2 625 327 3,85% 5,97% 2 625 327 3,73% 5,82% 2 625 327 3,61% 5,67% Actions in the pact 1 123 902 1,65% 4,24% 1 123 902 1,59% 4,13% 1 123 902 1,54% 4,02% Actions outside the pact 1 501 425 2,20% 1,74% 1 501 425 2,13% 1,69% 1 501 425 2,06% 1,65% Total concert 22 243 723 32,62% 37,74% 22 243 723 31,56% 36,78% 22 243 723 30,58% 35,86% Other investors above 5% 6 888 610 10,10% 9,33% 6 888 610 9,78% 9,09% 6 888 610 9,47% 8,86% Other investors 39 060 475 57,28% 52,93% 41 337 262 58,66% 54,14% 43 614 049 59,95% 55,28% Total 68 192 808 100,00% 100,00% 70 469 595 100,00% 100,00% 72 746 382 100,00% 100,00% (1) All classes of shares are affected. The number of ordinary shares amounts to 61,430,129 before the Private Placement, 63,706,916 after the Private Placement (but before exercise of the BSAs), and 65,983,703 after the Private Placement and exercise of the BSAs.(2) The diluted basis takes into account the exercise of all instruments giving access to the capital, the definitive allocation of all free shares and the conversion of all preferred shares into ordinary shares (aiming for the highest theoretical dilution).(3) AMY SAS is a company controlled by A. Moussy. On the basis of the share capital of the Company immediately after completion of the Private Placement, the interest of a shareholder who held 1.00% of the Company's share capital prior to the above-mentioned capital increase and who did not subscribe to it now stands at 0.97% on a non-diluted basis and 0.77% on a diluted basis. Admission to trading of the New Shares The New Shares are expected to be admitted to trading on the regulated market of Euronext Paris on August 7, 2025. The New Shares will be subject to the provisions of the Company's by-laws and will be assimilated to existing shares upon final completion of the Private Placement. They will bear current dividend rights and will be admitted to trading on the same listing line as the Company's existing shares under the same ISIN code FR0010557264 – AB. Lock-up commitments The Company has signed a lock-up commitment (to the benefit of the investors) pursuant to which it has agreed to a lock-up period of 45 calendar days from the date of the settlement and delivery of the Private Placement, subject to certain customary exceptions. The directors and officers of the Company have signed a lock-up commitment pursuant to which they have agreed to a lock-up period of 90 calendar days from the date of the settlement and delivery of the Private Placement, subject to certain customary exceptions. Indicative timetable July 24, 2025 Decisions of the Board of Directors deciding the principle of the Private Placement. August 1st, 2025 Decisions of the Chief Executive Officer setting the terms and conditions of the Private Placement (including the subscription price of the ABSAs and the gross amount of the Private Placement). August 4, 2025 Publication of this press of the Information Document. August 7, 2025 Publication of the Euronext notice of admission of the New Shares to trading on Euronext Paris. August 7, 2025 Settlement-delivery of the ABSAs - Detachment of the BSA - Start of trading of the New Shares on Euronext Paris. August 11, 2025 Admission of the BSAs on Euronext Growth Paris. Risk factors AB Science draws the attention of the public to the risk factors relating to the Company and its business described in its annual management reports and press releases, which are available free of charge on the Company's website ( In addition, the main risks specific to securities are as follows: The existing shareholders who do not participate in the Private Placement will see their shareholding in the share capital of AB Science diluted, and this shareholding may also be diluted in the event of exercise of the BSA, as well as in the event of new securities transactions. The volatility and liquidity of AB Science shares could fluctuate significantly. The market price of the Company's shares may fluctuate and fall below the subscription price of the shares issued in the context of the Private Placement. The sale of Company shares may occur on the secondary market, after the Private Placement, and have a negative impact on the Company share price. About masitinib Masitinib is a novel oral tyrosine kinase inhibitor that is being developed to target mast cells and macrophages, key immune cells, through inhibition of a limited number of kinases. Due to its unique mode of action, the Company believed that masitinib can be developed in a wide range of diseases, including oncology, inflammatory diseases, and certain central nervous system diseases. In oncology, through its immunotherapy activity, masitinib may have an effect on survival, alone or in combination with chemotherapy. Through its activity on mast cells and microglial cells and therefore its inhibitory effect on the activation of the inflammatory process, masitinib may have an effect on the symptoms associated with certain inflammatory and central nervous system diseases. About AB8939 AB8939 is a new synthetic microtubule-destabilizing drug candidate. Preclinical data suggests that AB8939 has broad anticancer activity, with a notable advantage over standard chemotherapies that target microtubules of being able to overcome P-glycoprotein (Pgp) and myeloperoxidase (MPO) mediated drug resistance. Development of drug resistance often restricts the clinical efficacy of microtubule-targeting chemotherapy drugs (for example, taxanes and vinca alkaloids); thus, AB8939 has the potential to be developed in numerous oncology indications. About AB Science Founded in 2001, AB Science is a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), a class of targeted proteins whose action are key in signaling pathways within cells. Our programs target only diseases with high unmet medical needs, often lethal with short term survival or rare or refractory to previous line of treatment. AB Science has developed a proprietary portfolio of molecules and the Company's lead compound, masitinib, has already been registered for veterinary medicine and is being developed in human medicine in oncology, neurological diseases, inflammatory diseases and viral diseases. The company is headquartered in Paris, France, and listed on Euronext Paris (ticker: AB). Further information is available on AB Science's website: Disclaimer This press release and the information contained herein do not constitute an offer to subscribe or purchase, or the solicitation of an order to purchase or subscribe, for the New Shares in the United States of America or in any other jurisdiction. Securities may not be offered or sold in the United States of America absent registration under the U.S. Securities Act or an exemption from registration under the U.S. Securities Act. AB Science does not intend to make a public offering of the New Shares in the United States of America or in any other jurisdiction. The distribution of this press release may be subject to legal or regulatory restrictions in certain countries. Persons in possession of this press release should inform themselves of and observe any local restrictions. The information contained herein is subject to change without notice. This information contains forward-looking statements, which are not guarantees of future performance. These statements are based on the current expectations and beliefs of AB Science's management and are subject to several factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. AB Science and its affiliates, directors, officers, employees, consultants or agents do not undertake, and are not under any obligation, to release any updates to any forward-looking statement or to revise any forward-looking statement. For additional information, please contact: AB Science Financial communication and public relationsinvestors@ 1Based on the volatility overt the last 12 months of the Euronext Next Biotech index. Attachment AB Science - August 2025 Press Release US VFSign in to access your portfolio
Yahoo
10-03-2025
- Business
- Yahoo
PepGen Announces Presentations at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference
BOSTON, March 10, 2025--(BUSINESS WIRE)--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that the Company will be presenting two oral presentations as well as five posters at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference, being held March 16-19, 2025 in Dallas, TX. The oral presentations feature data from the ongoing CONNECT1-EDO51 clinical trial in Duchenne muscular dystrophy (DMD) and from the ongoing FREEDOM-DM1 clinical trial in myotonic dystrophy type 1 (DM1), which the Company recently announced. Oral Presentations Title: CONNECT1-EDO51: A 12-Week Open-Label Phase 2 Study to Evaluate PGN-EDO51 Safety and Efficacy in People with Duchenne Amenable to Exon 51 SkippingSession: Clinical Trial UpdatesDate & Time: Wednesday, March 19th at 8:45-9:00 a.m. CTPresenter: Paul Streck, MD, MBA, Executive Vice President, R&D Title: FREEDOM-DM1: A Phase 1, Placebo-Controlled Single Ascending Dose Study to Evaluate PGN-EDODM1 in People with Myotonic Dystrophy Type 1 (DM1)Session: Clinical Trial UpdatesDate & Time: Wednesday, March 19th at 12:45-1:00 p.m. CTPresenter: Jane Larkindale, DPhil, Vice President, Clinical Science Poster Presentations Posters will be displayed beginning at 6:00-8:00 p.m. CT on Sunday, March 16th through Tuesday, March 18th in the conference exhibit hall. Title: Mechanistic Characterization of Enhanced Delivery Oligonucleotide (EDO) PlatformPoster Number: #P21Presenter: Jane Larkindale, DPhil, Vice President, Clinical Science Title: Nonclinical Data for PGN-EDODM1 Demonstrated Mechanistic and Meaningful Activity for the Potential Treatment of DM1Poster Number: #P48Presenter: Ashling Holland, PhD, Director, Research & Preclinical Development Title: Single- and Repeat-Dose Nonclinical Data for PGN-EDO51 Demonstrated Favorable Pharmacology and Safety Profiles for the Treatment of DMDPoster Number: #P49Presenter: Ashling Holland, PhD, Director, Research & Preclinical Development Title: FREEDOM-DM1: A Phase 1, Placebo-Controlled Single Ascending Dose Study to Evaluate PGN-EDODM1 in People with Myotonic Dystrophy Type 1 (DM1)Poster Number: #O45Presenter: Jennifer Shoskes, PharmD, Associate Director, Clinical Development Title: CONNECT1-EDO51: A 12-Week Open-Label Phase 2 Study to Evaluate PGN-EDO51 Safety and Efficacy in People with Duchenne Amenable to Exon 51 SkippingPoster Number: #O74Presenter: Bassem Morcos, MD, Medical Director, Clinical Development Following the conference, the presentations presented at the MDA Clinical & Scientific Conference will be available on the Investors page of PepGen's website under Scientific Publications. About PGN-EDODM1 PGN-EDODM1, PepGen's investigational candidate in development for the treatment of DM1, utilizes the Company's proprietary EDO technology to deliver a therapeutic oligonucleotide that is designed to restore the normal splicing function of MBNL1, a key RNA splicing protein. PGN-EDODM1 is designed to directly address the deleterious effects of cytosine-uracil-guanine (CUG) repeat expansion in the DMPK transcripts which sequester MBNL1, by binding to the pathogenic CUG trinucleotide repeat expansion present in the DMPK transcripts, disrupting the binding between the CUG repeat expansion and MBNL1. We believe this mechanism will allow the DMPK transcripts to continue performing its normal function within the cell, while also liberating MBNL1 to correct downstream mis-splicing events. We believe that this innovative therapeutic approach has considerable advantages over oligonucleotide modalities that rely on knockdown or degradation of the DMPK transcripts. The FDA has granted PGN-EDODM1 both Orphan Drug and Fast Track Designations for the treatment of patients with DM1. About PGN-EDO51 PGN-EDO51, PepGen's investigational candidate in development for the treatment of DMD, utilizes the Company's proprietary EDO technology to deliver a therapeutic oligonucleotide that is designed to target the root cause of this devastating disease. PGN-EDO51 is designed to skip exon 51 of the dystrophin transcript, an established therapeutic target for approximately 13% of DMD patients, thereby aiming to restore the open reading frame and enabling the production of a truncated, yet functional dystrophin protein. The FDA has granted PGN-EDO51 both Orphan Drug and Rare Pediatric Disease Designations for the treatment of patients with DMD amenable to an exon-51 skipping approach. About PepGen PepGen is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases. PepGen's EDO platform is founded on over a decade of research and development and leverages cell-penetrating peptides to improve the uptake and activity of conjugated oligonucleotide therapeutics. Using these EDO peptides, we are generating a pipeline of oligonucleotide therapeutic candidates designed to target the root cause of serious diseases. For more information, please visit Follow PepGen on LinkedIn and X. View source version on Contacts Investor Dave Borah, CFASVP, Investor Relations and Corporate Communicationsdborah@ Media Julia DeutschLyra Strategic AdvisoryJdeutsch@
Yahoo
30-01-2025
- Business
- Yahoo
Science Exchange Announces New Clinical Development Solution
Addressing the complexity of FSP and FSO outsourcing models, this new solution, powered by Science Exchange's supplier orchestration platform, modernizes clinical supplier collaboration and budget management. PALO ALTO, Calif., January 30, 2025--(BUSINESS WIRE)--Science Exchange, the leading SaaS provider of supplier orchestration solutions for the life sciences industry, today announced the launch of its Clinical Development Solution. Designed to address the unique challenges faced by clinical operations and procurement teams managing outsourced clinical studies, the platform provides pharmaceutical sponsors with the tools to efficiently orchestrate the entire contracting and collaboration process across suppliers—whether in functional service provider (FSP) or full-service outsourcing (FSO) models. The Business Process Challenge in Clinical Development Clinical trials, especially large-scale studies such as oncology trials, involve increasingly complex outsourcing arrangements. The shift from full-service outsourcing (FSO) to functional service provider (FSP) models has created new operational burdens for clinical operations teams. In an FSP model, sponsors directly manage a diverse set of specialized suppliers responsible for various trial components, requiring greater coordination and oversight. Key business process challenges include: Study Intake and RFI/RFP Management: Coordinating RFIs and RFPs for specialized services becomes time-intensive, often managed via email and spreadsheets. Budget Lifecycle and Rate Card Validation: Ensuring supplier budgets align with pre-negotiated rate cards in MSAs requires meticulous review and introduces risks of errors. Collaboration Between Stakeholders: Communication across sponsors and multiple vendors often lacks a central hub and is done via email, leading to potential communication silos and downstream budget errors. Tracking Change Orders: Managing budget amendments and ensuring proper documentation is a manual, fragmented process that often relies on complex Excel models and PDFs. Spend and Payment Processing Transparency: Consolidating data from diverse suppliers for reporting and analysis is a significant challenge, particularly around invoices and attribution of invoices to specific budget lines. These challenges are common across the full lifecycle of clinical trials and highlight the critical need for a digital supplier orchestration platform purpose-built for clinical development operations. Modernizing Clinical Operations with Supplier Orchestration Software The Science Exchange Clinical Development Solution addresses these pain points head-on, empowering sponsors with a centralized platform to manage the complexities of FSP and FSO models. Key features include: Digital Workspaces: Streamline all supplier engagements, budgets, and contracts on a single platform, providing visibility and control across the trial lifecycle. On-Cloud Budget Grids: Digital budget grids enable strong budget compliance and reduce version control errors. Rate Card Compliance Automation: Automatically validate budget lines against supplier-specific rate cards in MSAs, flagging discrepancies to ensure compliance at the line level. Real-Time Collaboration: Foster seamless communication between sponsors and vendors, eliminating the silos that often delay trials. Change Order Log Management: Digitize the process of tracking and approving budget modifications, ensuring an audit trail for compliance. Spend Data Mining: Centralize and validate supplier spend data at the budget line level to generate actionable insights and ensure alignment with trial budgets, whether at the study or program levels. "In an era where R&D budget complexity threatens strategic decision-making, Science Exchange's clinical development solution acts like a digital Rosetta Stone. By converting fragmented PDF and Excel data into structured, actionable intelligence, they're not just digitizing budgets—they're transforming how life sciences organizations unlock hidden financial insights. Imagine having instant, granular visibility into every budget line item, enabling precision cost optimization that was previously impossible," said Wynn Bailey, a former partner at PwC, Life Sciences Operations practice. The Science Exchange Clinical Development Solution is a transformative step forward for the industry, addressing the operational burdens of increasingly complex outsourcing models. By enabling sponsors to bring their supplier engagements, budgets, and collaboration processes onto a single technology platform, Science Exchange is paving the way for faster, more efficient clinical trials. "The shift to FSP outsourcing models has introduced unprecedented challenges for clinical operations teams, particularly in managing a growing network of specialized suppliers," said Elizabeth Iorns, CEO and Co-Founder at Science Exchange. "Our orchestration platform is purpose-built to address these challenges, providing sponsors with the technology to digitize, automate, and streamline their workflows across all components of clinical development. Whether it's a central labs study or a complex Phase 3 oncology trial, the solution is designed to deliver efficiency, transparency, and process compliance." Explore our new solution Join our webinar: Supplier Orchestration in Action: Modernizing Clinical Operations through Technology | Wednesday, February 26 | 10:00 AM PT / 1:00 PM ET Read our blog post: Navigating the Shift to FSP Models: Addressing the Complexity of Clinical Development with Supplier Orchestration. Visit our website: Clinical Development Solution page. About Science Exchange Science Exchange is the first procurement and supplier orchestration cloud software platform for life sciences companies. The platform digitizes and streamlines complex procurement workflows spanning the entire purchasing lifecycle, from vendor and product discovery through purchasing and payment. Many of the world's top pharma and biotech organizations rely on Science Exchange to help accelerate their research, automate manual processes, and advance their programs faster. For additional information on Science Exchange, please visit View source version on Contacts Media Contact: Kelly Science Exchange Sign in to access your portfolio
